DWTX — Dogwood Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
$2.53
-$0.10 (-3.80%)
Dogwood Therapeutics, Inc. (DWTX) is a biotechnology company listed on NASDAQ. It is led by Gregory Duncan, based in 44 Milton Avenue, Alpharetta, GA, United States, 30009, with about 12 employees. Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.
Net income was -$30.5M. DWTX currently screens at market cap $8.2M.
Use this DWTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the DWTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the DWTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Dogwood Therapeutics, Inc. even when a live quote feed is slow.
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.
DWTX Key Statistics
Market Cap
$8.17M
Volume
122,382
Previous Close
$2.56
Day Range
$2.53 – $2.68
EPS
-$12.52
Revenue
$0.00
Net Income
-$12.35M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
12
DWTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$12.35M | -$5.30M | -$12.25M | -$15.96M |
| EPS (Diluted) | -$12.52 | -$7.05 | -$1.11 | -$1.92 |
Total Assets
$94.31M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$14.85M
Operating Cash Flow
-$8.79M
Free Cash Flow
$0.00
Dogwood Therapeutics, Inc. Company Information
- Chairman & CEO
- Gregory Duncan
- Headquarters
- 44 Milton Avenue, Alpharetta, GA, United States, 30009
- Website
- dwtx.com
- Phone
- 866 620 8655
- IPO / Founded
- 2020-12-17
- Sector
- Healthcare
- Industry
- Biotechnology